A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; MCY-M11 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Sponsors MaxCyte
- 30 Aug 2021 Status changed from active, no longer recruiting to discontinued.
- 22 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2020 Treatments section is updated with the addition of Intravenous Cyclophosphamide for pre-conditioning- this will be done in some patients of Cohorts 2,3 and 4 and those sub-groups within these cohorts are termed as-Cohort 2i, 3i and 4i respectively. Planned number of patients to be enrolled is increased from 15 to 27.